Perspective Therapeutics Charts New Course with CFO Appointment Amid Technical Concerns

The company formerly known as IsoRay has undergone a significant transformation. Following its merger with Viewpoint Molecular Targeting, the entity now operates as Perspective Therapeutics, Inc. and trades on the market under the ticker symbol CATX, marking a strategic pivot to focus exclusively on the radiopharmaceuticals sector. This corporate evolution coincides with a pivotal leadership appointment and a challenging technical outlook for its shares.

Recent market performance presents a concerning picture for investors. As of September 3, 2025, CATX shares were valued at $3.38, with the company’s market capitalization standing at $249.89 million. The stock’s 52-week range has been wide, fluctuating between a low of $1.60 and a high of $16.31.

A detailed technical analysis reveals a bearish consensus Read more...